Market Research Logo

Global Cancer Diagnostics Device Market 2016-2020

About the Cancer Diagnostic Devices Market

An increase in any particular internal and external factor can lead to cancer. Currently, the demand for cancer therapy and research in complex molecular tumor diagnostics is high. Researchers are using automated solutions to isolate genetic materials from small tissue samples. The complex genetic analysis of samples using next-generation sequencing technologies helps researchers analyze the individual and relevant pattern of genetic changes in tumor tissues, helping in determining the most effective treatment options. The development of sophisticated technologies such as microarray, next-generation sequencing, mass spectrometry, automated DNA sequencing, fluorescence in-situ hybridization, and comparative genomic hybridization has opened new avenues for cancer biomarkers. These technologies are capable of detecting abnormalities in the gene expression and the genetic structure of cancer cells. In addition, these technologies can analyze changes in the DNA, RNA, and chromosomes from tissue samples of a tumor.

Technavio’s analysts forecast the global cancer diagnostics devices market to grow at a CAGR of 18.07% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global cancer diagnostics devices market for 2016-2020 To calculate the market size, we consider revenue generated from the sales of molecular and companion cancer diagnostic devices.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Cancer Diagnostics Devices Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Abbott Diagnostics
  • Agilent Technologies
  • BD
  • bioMérieux
  • Qiagen
  • Roche Diagnostics
Other prominent vendors
  • Affymetrix
  • Ambry Genetics
  • Annoroad
  • Aviva Biosciences
  • Biochain
  • Bio-Rad
  • Cancer Genetics
  • Cepheid
  • CompanionDx
  • DiagnoCure
  • Epic Sciences
  • Epigenomics
  • Genomic Health
  • HalioDX
  • Hologic
  • Illumina
  • Myriad Genetics
  • Thermo Fisher Scientific
  • Ventana Medical Systems
  • Vysis
Market driver
  • Demand for personalized medicines
  • For a full, detailed list, view our report
Market challenge
  • High cost of developing companion diagnostics
  • For a full, detailed list, view our report
Market trend
  • Demand for personalized medicines
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Cancer Diagnostic Devices Market 2016-2020

Technavio recognizes the following companies as the key players in the global cancer diagnostics devices market: Abbott Diagnostics, Agilent Technologies, BD, bioMérieux, Qiagen, and Roche Diagnostics.

Other Prominent Vendors in the market are: Affymetrix, Ambry Genetics, Annoroad, Aviva Biosciences, Biochain, Bio-Rad, Cancer Genetics, Cepheid, CompanionDx, DiagnoCure, Epic Sciences, Epigenomics, Genomic Health, HalioDX, Hologic, Illumina, Myriad Genetics, Thermo Fisher Scientific, Ventana Medical Systems, and Vysis.

Commenting on the report, an analyst from Technavio’s team said: “A trend which will definitely boost market growth is product approvals and launches. The significant focus on cancer diagnosis has led to the development of novel cancer diagnostic devices in the market. Many of these products have received approval from regulatory agencies such as the FDA and Health Canada. The availability of these advanced tests and associated diagnostic devices has allowed medical facilities to adopt them for cancer diagnosis. For instance, Beckman Coulter's VERIS molecular diagnostic system and VERIS human cytomegalovirus assay received CE mark approval in May 2014.”

According to the report, a key growth driver is the demand for personalized medicines. Proteins and genes control and manage the biochemical functions of the body. Any defect in the structure of a particular protein or gene can lead to specific conditions and disorders. The production of personalized drugs depends on the identification and study of protein and gene expressions. These drugs are customized based on an individual's protein or genetic profiles. Personalized medicines have high demand in oncology therapy since conventional cancer drug therapies fail to achieve desired patient outcomes.

Further, the report states that one challenge that could impact market growth is the high cost of developing companion diagnostics.



Companies Mentioned

Abbott Diagnostics, Agilent Technologies, BD, bioMérieux, Qiagen, Roche Diagnostics, Affymetrix, Ambry Genetics, Annoroad, Aviva Biosciences, Biochain, Bio-Rad, Cancer Genetics, Cepheid, CompanionDx, DiagnoCure, Epic Sciences, Epigenomics, Genomic Health, HalioDX, Hologic, Illumina, Myriad Genetics, Thermo Fisher Scientific, Ventana Medical Systems, Vysis.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Cancer statistics
    • Table Prevalent cancer types worldwide 2012
    • Table Top countries with highest cancer rate worldwide 2012
    • Table Cancer statistics by gender 2012
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global cancer diagnostic devices market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Reimbursement and coverage: An overview
    • Current scenario: Validating diagnostic tests
    • Reimbursement structure in US
    • Reimbursement structure in EU
      • Table Reimbursement perspectives of healthcare entities
  • Cancer diagnostic devices: Pricing scenario
    • Table Factors influencing cost of cancer diagnostic devices
  • Market segmentation by product
    • Table Global cancer diagnostic devices market segmentation by product
    • Global companion cancer diagnostic devices market
      • Table Global companion cancer diagnostic devices market 2015-2020 ($ millions)
    • Global molecular cancer diagnostic devices market
      • Table Global molecular cancer diagnostic devices market 2015-2020 ($ billions)
  • Market segmentation by cancer type
    • Table Global cancer diagnostic devices market segmentation by cancer type 2015
    • Lung cancer
    • Breast cancer
    • Colorectal cancer
    • Prostate cancer
    • Cervical cancer
      • Table Cancer types and associated diagnosis methods
  • Geographical segmentation
    • Table Global cancer diagnostic devices market segmentation by geography 2015
    • Table Global cancer diagnostic devices market segmentation by geography 2020
    • Table Global cancer diagnostic devices market segmentation by geography 2015-2020 ($ millions)
    • Table Global cancer diagnostic devices market segmentation by geography 2015-2020
    • Cancer diagnostic devices market in Americas
      • Table Cancer diagnostic devices market in Americas 2015-2020 ($ billions)
    • Cancer diagnostic devices market in EMEA
      • Table Cancer diagnostic devices market in EMEA 2015-2020 ($ millions)
    • Cancer diagnostic devices market in APAC
      • Table Cancer diagnostic devices market in APAC 2015-2020 ($ millions)
  • Market drivers
    • Prevalence of cancer
    • Need for cost-cutting in drug discovery and development
    • Demand for personalized medicines
    • Advances in technology
    • Focus on emerging countries
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Unfavorable reimbursement scenario
    • High cost of developing companion diagnostics
    • Stringent regulatory framework
    • Lack of skilled personnel
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Adoption of various strategies
    • Increase in R&D
    • Product approvals and launches
  • Vendor landscape
    • Competitive scenario
    • Keys news
    • M&A
  • Key vendors
    • Abbott Diagnostics
      • Table Abbott Diagnostics: Product portfolio
      • Table Abbott Diagnostics: Key takeaways
    • Agilent Technologies
      • Table Agilent Technologies: Product portfolio
      • Table Agilent Technologies: Revenue of diagnostics and genomics segment 2013-2015 ($ millions)
      • Table Agilent Technologies: Key takeaways
    • BD
      • Table BD: Product portfolio
      • Table BD: Revenue of life sciences segment 2013-2015 ($ billions)
      • Table BD: Key takeaways
    • bioMérieux
      • Table bioMérieux: Product portfolio
      • Table bioMérieux: Key takeaways
    • Qiagen
      • Table Qiagen: Product portfolio
      • Table Qiagen: Revenue of consumable and related products 2013-2015 ($ billions)
      • Table Qiagen: Key takeaways
    • Roche Diagnostics
      • Table Roche Diagnostics: Product portfolio
      • Table Roche Diagnostics: Revenue of molecular diagnostics segment 2013-2015 ($ billions)
      • Table Roche Diagnostics: Key takeaways
    • Other prominent vendors
      • Table Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report